Guardant Health (GH) Reports Q4 Revenue of $280M, Up 39% Year Over Year
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 12 2026
0mins
Source: seekingalpha
- Revenue Beats Expectations: Guardant Health reported Q4 revenue of $280 million, a 39% year-over-year increase, surpassing the consensus estimate of $267.75 million, indicating strong demand in oncology and screening tests that solidifies the company's market position in precision medicine.
- Significant Test Volume Growth: The company conducted approximately 79,000 oncology tests in Q4, representing a 38% increase from the prior year, while Shield screening tests surged to about 38,000 from 6,400 in the same period last year, reflecting strong market demand for its innovative products.
- Impressive Full-Year Performance: Guardant Health anticipates total revenue of approximately $981 million for 2025, a 33% year-over-year increase, slightly above the consensus estimate of $968.56 million, showcasing the company's sustained growth potential in the oncology sector.
- Cash Flow Status: Despite a negative free cash flow of approximately $54 million in Q4 and negative $233 million for the full year 2025, the company reported approximately $1.3 billion in cash and cash equivalents as of December 31, 2025, ensuring funding support for future investments and operations.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like GH with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on GH
Wall Street analysts forecast GH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GH is 124.69 USD with a low forecast of 105.00 USD and a high forecast of 155.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
19 Analyst Rating
18 Buy
1 Hold
0 Sell
Strong Buy
Current: 109.730
Low
105.00
Averages
124.69
High
155.00
Current: 109.730
Low
105.00
Averages
124.69
High
155.00
About GH
Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx test, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. It offers other tests, including Guardant360 Tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Guardant Health's Guardant360 CDx Approved by FDA as Companion Diagnostic for mCRC Treatment
- FDA Approval: Guardant Health's Guardant360 CDx has received FDA approval as a companion diagnostic for identifying patients with BRAFV600E-mutant metastatic colorectal cancer, marking a significant expansion in the company's precision medicine capabilities.
- Clinical Trial Support: The accelerated approval for Braftovi is backed by data from Pfizer's Phase 3 BREAKWATER trial, which demonstrated significant improvements in objective response rates and survival, likely boosting market demand for the associated therapies.
- Non-Invasive Testing Advantage: Guardant360 CDx is the first FDA-approved liquid biopsy that detects multiple genomic alterations through a simple blood draw, enhancing access to treatment for high-risk patients, particularly when tumor tissue samples are insufficient.
- Strong Financial Performance: Guardant Health anticipates revenues of $981 million in 2025, a 33% year-over-year increase, and analysts expect a slight improvement in earnings per share in the upcoming report, reflecting positive market sentiment regarding its growth prospects.
Continue Reading
Guardant Health (GH) Receives FDA Approval for Guardant360 CDx Diagnostic to Enhance Colorectal Cancer Treatment
- FDA Approval: The US FDA has approved Guardant Health's Guardant360 CDx companion diagnostic, which determines which patients with BRAF V600E-mutant metastatic colorectal cancer could benefit from Pfizer's Braftovi (encorafenib), providing more precise treatment options for patients.
- Blood Test Advantage: Guardant360 CDx utilizes a small blood sample to detect genetic mutations, enhancing testing convenience and accelerating treatment decisions for patients, thereby improving survival rates and quality of life.
- Broad Market Potential: With the increasing demand for personalized medicine among colorectal cancer patients, this new diagnostic is expected to drive revenue growth for Guardant Health in the future and solidify its market position in precision medicine.
- Optimistic Performance Outlook: Guardant Health's revenue guidance for Q4 and FY25 exceeds market expectations, indicating strong performance in the healthcare services sector and further boosting investor confidence in its future growth.
Continue Reading